Newblue-CHEM - Ima...

Newblue-CHEM - Imatinib

Newblue-CHEM - Imatinib

Min.Order / FOB Price:Get Latest Price

1 Gram

FOB Price: USD 1000.0000

  • Min.Order :1 Gram
  • Purity: 99.0%
  • Payment Terms : L/C,D/A,D/P,T/T,Other

Keywords

Imatinib 152459-95-5 C29H31N7O

Quick Details

  • Appearance:Solid
  • Application:Organic synthesis
  • PackAge:IN 25kg drums
  • ProductionCapacity:10|Metric Ton|Month
  • Storage:In Room Temperature
  • Transportation:As per MSDS

Superiority:

Henan Newblue Chemical Co., Ltd. is located in Zhengzhou High-tech Development Zone with import and export license.

We passed ISO 9001:2008 in 2009, and won "High-tech Enterprise" by provincial government in 2013.The objective of the company is to put quality first and put our customer’s needs first - the satisfaction of our customers is the company's ultimate goal.

Improving product quality and service level is our responsibility, and creating more value for our customer’s is our purpose. We are constantly striving to make Henan Newblue a leading chemical supplier, and hope to create a better future with you.

Details:

Imatinib Basic information
Product description Approved indications in Europe, the United States and other countries Precautions Uses
Product Name: Imatinib
Synonyms: 4-(4-METHYL-PIPERAZIN-1-YLMETHYL)-N-[4-METHYL-3-(4-PYRIDIN-3-YL-PYRIMIDIN-2-YLAMINO)-PHENYL]-BENZAMIDE;Imatinib (4-[(4-Methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]benzamide;Imatinib free base;Veenat;IMatinib(STI571);Imantinib base;4-(4-Methyl-piperazin-1-ylMethyl)-N-[4-Methyl-3-(4-pyridin-3-yl-pyriMidin-2-ylaM;IMatinib-D4
CAS: 152459-95-5
MF: C29H31N7O
MW: 493.6
EINECS:
Product Categories: Pharmaceutical intermediate;Imatinib;Aromatics;Heterocycles;Impurities;Intermediates & Fine Chemicals;Pharmaceuticals;API;GLEVEEC;Antineoplastic;Anti-cancer & immunity;Inhibitors;Molecular Targeted Antineoplastic
Mol File: 152459-95-5.mol
Imatinib Structure
Imatinib Chemical Properties
Melting point 208-210°C (dec.)
storage temp. Refrigerator
pka pKa1 8.07; pKa2 3.73; pKa3 2.56; pKa4 1.52(at 25℃)
Merck 14,4902
CAS DataBase Reference 152459-95-5(CAS DataBase Reference)
Safety Information
Safety Statements 24/25
RTECS CV5585673
MSDS Information
Imatinib Usage And Synthesis
Product description Imatinib is a kind of oral drugs used for the treatment of the chronic myelogenous leukemia (abbreviated CML) of positive symptoms of Philadelphia chromosome (Ber-Abl). It is suitable for being applied to adult patients in acute transformation phase, accelerated phase, and chronic phase with treatment failure with interferon. CML is a kind of hematopoietic stem cell disease caused by the DNA abnormalities in the bone marrow stem cells. DNA abnormalities will produce abnormal proteins and interfere with the normal generation process of the white blood cells in the bone marrow, resulting in the sharp increase in the number of white blood cells. CML is divided into three phases including chronic phase, accelerated phase and crisis phase with the average survival period of the patients in crisis phase being only 2-3 months. 
Imatinib is also effective in treating the gastrointestinal stromal tumor with the efficiency being about 50%.
Approved indications in Europe, the United States and other countries Novartis's imatinib (imatinib, Glivec) had been approved in Switzerland for being used as first-line drug for the treatment of early-stage adult chronic myelogenous leukemia and can also be applied to patients with various types of chronic granulocytic leukemia. Switzerland is the first countries which had approved to additionally include the above two indications of this drug. 
On July 28, 2006, the European Agency for the Evaluation of Medicinal Products (EMEA) had recommended the imatinib (Gleevec) of the Novartis Company for the treatment of two new indications-dermatofibrosarcoma protuberans (DFSP) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph + ALL). These final approvals of these two indications still need to wait the decision of the European Food and Drug Administration. 
In addition, Novartis has announced that the application of imatinib in treating hypereosinophilic syndrome and systemic mastocytosis is still in the approval process of FDA and EMEA. 
The drug has currently been approved in Europe, the United States and other countries for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia (Ph + CML) and gastrointestinal stromal tumors. 
The above information is edited by the Chemicalbook of Dai Xiongfeng.
Precautions When combined with Ketoconazole, itraconazole, erythromycin, clarithromycin, the Cmax of this drug can (the maximum plasma concentration after the first drug administration) be increased by an average of 26% with the AUC being increased by 40%. 
The inducers of the metabolizing enzyme of hepatic drugs such as dexamethasone, phenytoin, carbamazepine, rifampicin and barbiturates can significantly reduce blood concentration of the drug. 
When the CYP3A4 metabolized substrates such as simvastatin, cyclosporine, pimozide, etc. were used in combined with imatinib, the plasma concentration of those drugs can be increased due to its competing with the drug enzyme.
Uses Imatinib can be used for the treatment of the chronic myelogenous leukemia (abbreviated CML) of positive symptoms of Philadelphia chromosome (Ber-Abl). It is suitable for being applied to adult patients in acute transformation phase, accelerated phase, and chronic phase with treatment failure with interferon.
Chemical Properties Orange Solid
Uses Imatinib Mesylate is orally bioavailability mesylate salt of Imatinib, which is a multi-target inhibitor of v-Abl, c-Kit and PDGFR with IC50 of 0.6 μM, 0.1 μM and 0.1 μM, respectively. Imatinib also known as Gleevec, Glivec, CGP-57148B, STI-571 & Imatinib
Uses antineoplastic
Uses atypical antipsychotic
Uses Imatinib impurity.
Imatinib Preparation Products And Raw materials
 

 

View All
Visit Store

You Might Also Like

Related Searches

Contact Supplier

Confirm to collect the product to my collection?

OKCancel

About|Contact|Cas|Product Name|Molecular|Country|Encyclopedia

Message|New Cas|MSDS|Service|Advertisement|CAS DataBase|Article Data|Manufacturers | Chemical Catalog

©2008 LookChem.com,License: ICP

NO.:Zhejiang16009103

complaints:service@lookchem.com Desktop View